Comparative efficacy of extracts from lycium barbarum bark and fruit on estrogen receptor positive human mammary carcinoma MCF-7 cells

Nutrition and Cancer

Volumn 66, Issue 2, 2014, Pages 278-284

  Telang, Nitin ^a   Li, Gou ^b   Sepkovic, Daniel ^c   Bradlow, H Leon ^c   Wong, George Y C ^b,d  

^a Cancer Prevention Research Program   (United States)

^b American Foundation for Chinese Medicine   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR; LYCIUM BARBARUM EXTRACT;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ARTICLE; BARK; BREAST CANCER; BREAST CARCINOMA; CELL GROWTH; CELL STRAIN MCF 7; CHEMICAL COMPOSITION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ESTROGEN METABOLISM; FRUIT; HERBAL MEDICINE; HUMAN; HUMAN CELL; IC 50; LYCIUM BARBARUM; NONHUMAN;

LYCIUM BARBARUM;

CELL PROLIFERATION; FRUIT; HUMANS; HYDROXYESTRONES; INHIBITORY CONCENTRATION 50; LYCIUM; MCF-7 CELLS; PLANT BARK; PLANT EXTRACTS; RECEPTORS, ESTROGEN;

EID: 84895119873     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2014.864776     Document Type: Article

References (32)

1. American Cancer Society: Facts&Figures 2012. American Cancer Society, Atlanta, 2012.
2. Sorlie T, Perou CM, Tibshirany R, Aas T, Geisler S, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 98, 10869-10874, 2001. (Pubitemid 32878711)
3. Perou CM, Sorlie T, Eisen MB, Johnson H, Geisler S, et al.: Molecular portraits of human breast tumors. Nature 406, 747-752, 2000.
4. Dinh P, Satiriou C, and Piccart MJ: The evaluation of treatment strategies: Aiming at the target. Breast 16 (Suppl. 2), S10-S16, 2007.
5. Molassiotis A, Scott JA, Kearney A, and Kearney N: Complementary and alternative use in breast cancer patients in Europe. Support Care Cancer 14, 206-267, 2006.
6. Rock E and De Michelle A: Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 133, S3785-S3793, 2003.
7. Hyler LK, Chin S, and Chui BK: The use of complementary and alternative medicines among patients with locally advanced breast cancer: a descriptive study. BMC Cancer 6, 39-46, 2006.
8. Tindle HA, Davis RB, Phillips RL, and Eisenberg DM: Trends in the use of complementary and alternative medicines by US adults: 1997-2002. Al tern Ther Health Med 11, 42-49, 2005. (Pubitemid 40110627)
9. Gau L, Hua Zhang S, Liang Yang X, and Bi Xu H: Immuno-modulation and anti-tumor activity by a polysaccharide protein complex from Lycium barbarum. Int J Immunopharmacol 4, 563-569, 2004.
10. Zhou S-F: Chinese herbal medicines for toxicity reduction in cancer chemotherapy. Aust J Acupunct Chinese Med 2, 30-31, 2007.
11. Lippman ME, Osborne CK, Knazeck R, and Young N: In vitro model systems for the study of hormone dependent human breast cancer. N Engl J Med 296, 154-159, 1977.
12. Li G, Sepkovic DW, Bradlow HL, Telang NT, and Wong GYC: Lycium barbarum inhibits growth of estrogen receptor positive human breast cancer cells by favorably altering estradiol metabolism. Nutrition and Cancer 61, 408-414, 2009.
13. Mukherjee B, Telang NT, and Wong GYC: Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellande tree. Int J Mol Med 24, 253-260, 2009.
14. Telang NT, Sepkovic DW, Bradlow HL, and Wong GYC: Chinese herb Fructus cornii exhibits preventive efficacy in a cell culture model for hormone responsive breast cancer. Cancer Res 70, S152-S153, 2010.
15. Telang N, Li G, Sepkovic DW, Bradlow HL, and Wong GYC: Comparative preventive efficacy of aqueous extracts from Lycium barbarum bark and fruit on estrogen receptor positive human mammary carcinoma MCF-7 cells. Cancer Res 71, 379S, 2011.
16. Telang NT, Li G, Sepkovic DW, Bradlow HL, and Wong GYC: Antiproliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor positive clinical breast cancer. Mol Med Rep 5, 22-28, 2012.
17. Suto A, Bradlow HL, Kubota T, Kitajima H, Wong GY, et al.: Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototype tumor suppressing agents. Steroids 58, 212-219, 1993.
18. Telang N, Li G, Katdare M, Sepkovic DW, Bradlow HL, et al.: Comparative preventive efficacy of select Chinese herbs in breast carcinoma derived isogenic cells with modulated estrogen receptor functions. Cancer Res 72, 190S, 2012.
19. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, et al.: Catechol estrogen production in rat microsomes after treatment with indole-3- carbinol, ascorbigen or ß-napthaflavone: a comparison of stable isotope dilution, gas chromatography-mass spectrophotometry and radiometric methods. Steroids 59, 318-323, 1994.
20. Dehnin L, Reiffsteck A, and Scholler R: Simple methods for the synthesis of twenty, different highly enriched deuterium labeled steroids suitable as internal standards for isotope dilution mass spectrophotometry. Biochem Mass Spectrometry 7, 493-499, 1980. (Pubitemid 11157460)
21. Raju U, Sepkovic DW, Dixon JM, Bradlow HL, and Levitz M: Estrone and estradiol metabolism in vivo in human breast cysts. Steroids 65, 883-888, 2000.
22. Lippman ME: Efforts to combine endocrine and chemotherapy in the management of breast cancer: do two and two equals three? Breast Cancer Res Treat 3, 117-127, 1983. (Pubitemid 13040290)
23. Early Breast Trialist's Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 years survival: an overview of the randomized trials. Lancet 365, 1687-1717, 2005.
24. Jordan VC: Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 24, A3-A16, 2002.
25. Schneider J, Kinne D, Frachia A, Pierce V, Anderson KE, et al.: Abnormal oxidative metabolism of 17ß-estradiol in women with breast cancer. Proc Natl Acad Sci USA 79, 3047-3051, 1982. (Pubitemid 12058614)
26. Fishman J, Schneider J, Herschkopf RJ, and Bradlow HL: Increased estrogen 16α-hydroxylase activity inwomenwith breast and endometrial cancer. J Steroid Biochem Mol Biol 20, 1077-1081, 1984. (Pubitemid 14101045)
27. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354, 270-282, 2006.
28. Fishman J, Osborne MP, and Telang NT: The role of estrogens in mammary carcinogenesis. Ann NY Acad Sci 768, 91-100, 1995.
29. Schneider J, Huh MM, Bradlow HL, and Fishman J: Anti-estrogen action of 2-hydroxyestrone on MCF-7 human breast carcinoma cells. J Biol Chem 259, 4840-4845, 1984. (Pubitemid 14144204)
30. Lottering ML, Haag M, and Segers JC: Effects of 17ß-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res 52, 5926-5932, 1992.
31. Telang NT, Suto A, Wong GY, Osborne MP, and Bradlow HL: Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84, 634-638, 1992.
32. Suto A, Telang NT, Tanino H, Takeshita T, Ohmiya H, et al.: In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites. Breast Cancer 6, 87-92, 1999.